What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness

Detalles Bibliográficos
Autores principales: Sekiguchi, Naohiro, Hamano, Airi, Kitagawa, Tomoko, Ito, Kenichi, Hirano, Kazuhiko, Yamada, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614101/
https://www.ncbi.nlm.nih.gov/pubmed/31309097
http://dx.doi.org/10.5045/br.2019.54.2.153
Descripción
Sumario:

Ejemplares similares